Mathias Bigger @BiggerMathias

Scientist turned investor at Bigger Capital biggercapital.com Las Vegas Joined October 2013

Tweets

69
Followers

244
Following

129
Likes

9K

Peter Mantas @peter_mantas

a day ago

This quote right here published today is the very definition of functional stability in a progressively deteriorating disease. That’s unequivocal AA territory. Might make a new diss track w/Drake and call it “back-to-back-to-back”. $QURE

4 11 87 15K 7

View Details

Michael Bigger @biggercapital

2 weeks ago

Whatever Koka Racha says KEBILIDI delivered this! Time to bring AMT-130 to HD patients youtube.com/shorts/6vqkWPD… $PTCT $CLPT $QURE

Peter Mantas @peter_mantas

2 weeks ago

New link that wasn't on the FDA site yesterday: fda.gov/science-resear…

5 2 47 19K 6

0 5 27 9K 1

View Details

Mathias Bigger @BiggerMathias

3 weeks ago

$CLPT always advancing. Just like $AMZN. 4 years of work wow, congratulations to Clearpoint and the Somocarelab.

ClearPointNeuro @ClearPointNeuro

3 weeks ago

#ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint - Read More Here: ir.clearpointneuro.com/news-events/pr… #CLPT

1 9 64 11K 3

0 2 20 2K 0

View Details

Mathias Bigger @BiggerMathias

a month ago

I agree that this is the smartest approach for evaluating the impact of a drug on the American people. It’s important that along with stakeholders, the patients, their families and the advocacy groups that support them can make informed commentary in the open. Their perspective acts as data points to determine the state of a treatment deprived community and the risk and urgency required in a situation. $QURE and the Huntington’s disease community stood strong, signed a petition 40k times and used X to openly challenge the decision the fda made. This dialogue is extremely valuable.

Houman David Hemmati, MD, PhD @houmanhemmati

a month ago

@RxRegA FDA must have the trust of the American people. Trust must be earned through transparency. The best form of transparency is to have everything out in the open and permit all stakeholders to view AND participate. Decisions cannot be made in a black box. This benefits review

6 4 47 2K 2

0 0 7 1K 0

View Details

Rich Law @drrichjlaw

a month ago

Feels like the FDA is slowly healing itself.

0 2 9 685 0

View Details

Mathias Bigger @BiggerMathias

a month ago

The FDA commissioner needs to be someone who understands that clinical biology is an approximate science, and when it comes to rare diseases any sign of efficacy needs to be nurtured and explored not thwarted and roadblocked. Based off of Houman’s tweets I think he’s an excellent candidate!

Houman David Hemmati, MD, PhD @houmanhemmati

a month ago

The FDA Commissioner role is open. This is a pivotal moment for American medicine — & for American patients. Here’s what I believe the next Commissioner should stand for. Not as a wish list. As a baseline. 🔬 1. BRING BACK THE ADCOMS — AND MAKE THEM COUNT. Advisory Committee

68 116 631 181K 58

3 10 115 37K 13

View Details

Mathias Bigger @BiggerMathias

a month ago

Totally agree Desert. Makary goes on media discussing his incredible progress at the FDA using accelerated pathways, data, and AI, then turns around and recommends a sham control when the comparative data already exists. For heavens sake the fda aligned on it in April 2025, Makary reneged. He does not have the interest of the patients in mind.

0 0 8 278 0

View Details

Mathias Bigger @BiggerMathias

a month ago

1. Put time pressure on $BEAT regulatory agent who then rejected their 12 lead ecg algorithm, they appealed and two weeks later it got approved 2. Claims that $QURE AMT 130 data is not enough to support approval, proceeds to go on cnbc and announce npmi and bash AMT130 saying it does not work. If the data wasn’t powered to meet his standards how can he then say the drug is ineffective? This slowed down AMT130 path to patients - costing them valuable time. 3. Other cases of pressuring his scientists to issue CRL and is forced to then review those very CRL due to outcry. 4. Introduced so much risk to biotech investing because the word of the FDA lost integrity. The companies who need cash to fund a trial based on the confidence of the fda alignment are struggling to raise money to fund trials.

0 1 11 716 0

View Details

Mathias Bigger @BiggerMathias

a month ago

Did not have the lives of patients in mind, show him the door. Prasad and Makary will be giving tutoring lessons next fall. $QURE $CLPT wsj.com/health/healthc…

1 3 23 1K 0

View Details

Mathias Bigger @BiggerMathias

a month ago

@idalopirdine @houmanhemmati

0 0 1 35 0

View Details

Dr. Toonces, MD, PhD @DrToonces

a month ago

President Trump just demonstrated something important. When he wants the FDA to act, the FDA acts. Per WSJ this week, he pressured Makary directly on flavored vapes and the agency reversed. Huntington's families have been waiting six months for that same intervention. AMT-130 works. The data is overwhelming. One conversation could change everything. $QURE #AMT130 wsj.com/politics/polic…

3 8 39 2K 1

View Details

Rick Santorum @RickSantorum

a month ago

I supported his nomination because he spoke truth during COVID. He immediately fired the best leaders at the FDA, replaced them with anti-Trump leftists who hollowed out FDA, harmed patients, stifled innovation & drove bio-tech to China then lied about it. wsj.com/opinion/presid…

42 46 223 104K 23

View Details

Dr. Toonces, MD, PhD @DrToonces

2 months ago

This is the smoking gun. A career FDA reviewer resigned over political pressure to block a rare disease drug, named Prasad directly, and said the review document supported approval. The HD community has been screaming this for 6 months. Now it’s on the Congressional record. #AMT130 $QURE

. @viatoCEO

2 months ago

Look at the full quotes from these career FDA scientists. Could it be any more clear that Prasad unilaterally torpedoed $QURE AMT-130? auchincloss.house.gov/media/press-re…

6 23 65 14K 7

4 15 69 6K 3

View Details

ClearPointNeuro @ClearPointNeuro

2 months ago

#ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint Read More Here: ir.clearpointneuro.com/news-events/pr… #CLPT

1 4 50 5K 0

View Details

AuxReignots @Reignots

2 months ago

Holy bullish for $CLPT - partners are undervalued, they are undervalued^2

0 2 18 2K 2

View Details

Rob Mani @ManRam930

2 months ago

Massive win for $CLPT! UCB just acquired Neurona Therapeutics for up to $1.15B to accelerate regenerative cell therapy for drug-resistant epilepsy. Every dose of NRTX-1001 is delivered via $CLPT. This is the kind of validation that moves the needle hard. Full speed ahead 🚀

0 4 19 2K 2

View Details

stepfanie tyler @stepfanie

2 months ago

If you hate billionaires, go all the way, pussy. Ditch the iPhone, the laptop, the tablet. Get off the internet. No Amazon, no big box stores, no Starbucks. Grow your own food. Thrift your clothes. Walk everywhere. And obviously no working for, buying from, or interacting with any company that scales beyond a farmers market. Enjoy your abundance.